Indications and Usage Mechanisms of Action Clinical Research Adverse reactions
ChemicalBook > CAS DataBase List > Sorafenib tosylate

Sorafenib tosylate

Indications and Usage Mechanisms of Action Clinical Research Adverse reactions
Product Name
Sorafenib tosylate
CAS No.
475207-59-1
Chemical Name
Sorafenib tosylate
Synonyms
CL050;Sorafenib &Sorafeni tosylate;SORAFENIB TOSYLATE;Sorafinib mesylate;Sorafenib (Nexavar);Sorafenib TsOH salt;Sorafenib 475207-59-1;Sorafenib tosylate-002;BAY 43-9006;BAY43-9006
CBNumber
CB92131200
Molecular Formula
C21H16ClF3N4O3.C7H8O3S
Formula Weight
637.03
MOL File
475207-59-1.mol
More
Less

Sorafenib tosylate Property

Melting point:
229-232°C
storage temp. 
2-8°C(protect from light)
solubility 
Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 3 mg/ml).
form 
solid
color 
Off-white
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.
InChI
InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
InChIKey
IVDHYUQIDRJSTI-UHFFFAOYSA-N
SMILES
S(C1C=CC(C)=CC=1)(O)(=O)=O.O(C1C=CC(NC(=O)NC2C=CC(Cl)=C(C(F)(F)F)C=2)=CC=1)C1=CC=NC(C(=O)NC)=C1
CAS DataBase Reference
475207-59-1(CAS DataBase Reference)
More
Less

Safety

Risk Statements 
36/37/38
Safety Statements 
28-26
HS Code 
29159000
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H362May cause harm to breast-fed children

H372Causes damage to organs through prolonged or repeated exposure

H410Very toxic to aquatic life with long lasting effects

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P263Avoid contact during pregnancy/while nursing.

P273Avoid release to the environment.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
Y0002236
Product name
Sorafenib for peak identification
Purity
European Pharmacopoeia (EP) Reference Standard
Packaging
Y0002236
Price
$202
Updated
2024/03/01
Sigma-Aldrich
Product number
Y0002224
Product name
Sorafenib tosilate
Purity
CRS, European Pharmacopoeia (EP) Reference Standard
Packaging
Y0002224
Price
$202
Updated
2024/03/01
Sigma-Aldrich
Product number
SML2633
Product name
Sorafenib tosylate
Purity
≥98% (HPLC)
Packaging
50MG
Price
$48.2
Updated
2024/03/01
TRC
Product number
S676845
Product name
SorafenibTosylate
Packaging
100mg
Price
$45
Updated
2021/12/16
Usbiological
Product number
289038
Product name
Sorafenib tosylate
Packaging
1g
Price
$440
Updated
2021/12/16
More
Less

Sorafenib tosylate Chemical Properties,Usage,Production

Indications and Usage

Sorafenib tosylate is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib tosylate is mainly used in advanced liver cancer treatment and is well tolerated.

Mechanisms of Action

Sorafenib tosylate can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.

Clinical Research

In a stage three randomized clinical study of American and European treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. One group received sorafenib tosylate, while the other received a placebo. Mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. The sorafenib tosylate group’s survival period was longer than that of the placebo group, with the risk ratio as 0.72. However, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison.
602 advanced liver cancer patients selected from the USA, Europe, Australia, and other countries and areas, who did not receive systematic treatment, were included in a study. Results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.

Adverse reactions

Manageable diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite.

Description

Sorafenib (475207-59-1) was initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinases including BRAF (IC50 = 22 nM); VEGFR-2 (IC50 = 90 nM); VEGFR-3 (IC50 = 20 nM); PDGFR-β (IC50 = 57 nM); Flt3 (IC50 = 58 nM); c-KIT (IC50 = 68 nM); FGFR-1 (IC50 = 580 nM).1?Paradoxically more potent in a cellular assay (IC50 = 20 nM) compared to an isolated enzyme assay (IC50 = 107 nM) for c-Fms.2?Inhibits activation of MAPK pathway and ERK phosphorylation.3?Induces caspase-independent apoptosis in melanoma cells.4?Sorafenib is a clinically useful anticancer agent.

Uses

Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.

Definition

ChEBI: Sorafenib tosylate is an organosulfonate salt. It contains a sorafenib.

brand name

Nexavar (Bayer).

General Description

Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and colon cancer.The agent is classified as a multikinase inhibitor because ofits action on numerous kinase enzymes including thePDGF-R, VEGF-R, Kit, and Raf. Sorafenib is 39% to 48% bioavailable and CYP3A4-mediated metabolism giveseight identified metabolites including the N-oxide, which isequally active with the parent. However, the majority of thedrug in plasma is present as the parent compound.Sorafenib is highly protein bound (99.5%). The drug iseliminated primarily in the feces (77%) with 19% appearingin the urine as glucuronides (UGT1A1) and has a eliminationhalf-life of 24 to 48 hours. The most commonly seentoxicity is skin rash that normally occurs within the first6 weeks of therapy. Other adverse effects include hypertension,fatigue, increased wound healing time, and increasedrisk of bleeding.

Clinical Use

Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent. It interferes with the growth of cancer cells, which are eventually destroyed by the body.

Side effects

The side effects of Sorafenib tosylate include Bleeding gums, blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet, bloating of the abdomen or stomach, blood in the urine or stools, clay-colored stools, coughing up blood, difficulty with breathing or swallowing, increased menstrual flow or vaginal bleeding.

target

Raf-1

References

1) Wilhelm et al. (2004), BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis; Cancer Res., 64 7099 2) Guo et al. (2006), Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors; Mol. Cancer Ther., 5 1007 3) Wilhelm et al. (2003), The novel Raf inhibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wildtype melanoma and colorectal tumor cell lies; Proc. Am. Assoc. Cancer Res., 44 106609 4) Panka et al. (2006), The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells; Cancer Res., 66 1611

Sorafenib tosylate Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Sorafenib tosylate Suppliers

LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
EMMX Biotechnology LLC
Tel
888-539-0666
Fax
888-539-0666
Email
info@emmx.com
Country
United States
ProdList
8447
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
Cato Research Chemicals Inc.
Tel
020-81215950 4000-868-328
Email
customer@uwalab.com
Country
United States
ProdList
10404
Advantage
58
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19881
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38631
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
United States Biological
Tel
--
Fax
--
Email
sales@advtechind.com
Country
United States
ProdList
6075
Advantage
58
Selleck Bio
Tel
--
Fax
--
Email
yukileoo@gmail.com
Country
United States
ProdList
6
Advantage
0
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
Focus Biomolecules
Tel
--
Fax
--
Email
sales@focusbiomolecules.com
Country
United States
ProdList
1284
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
Selleck Chemicals LLC
Tel
--
Fax
--
Email
sales@selleckchem.com
Country
United States
ProdList
1848
Advantage
58
Kare Bay Biochem Inc.
Tel
--
Fax
--
Email
product@karebaybio.com
Country
United States
ProdList
110
Advantage
58
Eton Bioscience, Inc.
Tel
--
Fax
--
Email
sales@etonbio.com
Country
United States
ProdList
3
Advantage
58
AstaTech, Inc.
Tel
--
Fax
--
Email
sales@astatechinc.com
Country
United States
ProdList
904
Advantage
58
SST Corporation
Tel
--
Fax
--
Email
info@sst-corp.com
Country
United States
ProdList
237
Advantage
38
OChem Incorporation
Tel
--
Fax
--
Email
sales@ocheminc.com
Country
United States
ProdList
6501
Advantage
60
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
Genegobio Inc.
Tel
--
Fax
--
Email
mark@genegobio.com
Country
United States
ProdList
195
Advantage
0
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
Axon Medchem LLC
Tel
--
Fax
--
Email
info@axonmedchem.com
Country
United States
ProdList
763
Advantage
58
Frontier Scientific, Inc.
Tel
--
Fax
--
Email
sales@frontiersci.com
Country
United States
ProdList
6222
Advantage
86
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Molcan Corporation
Tel
--
Fax
--
Email
info@molcan.com
Country
United States
ProdList
686
Advantage
60
Active Biopharma Corp
Tel
--
Fax
--
Email
support@activebiopharma.com
Country
United States
ProdList
82
Advantage
0
Focus Synthesis LLC
Tel
--
Fax
--
Email
acd@focussynthesis.com
Country
United States
ProdList
2487
Advantage
61
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
Tinib-Tools
Tel
--
Fax
--
Country
United States
ProdList
164
Advantage
0
Exlcusive Chemistry Ltd
Tel
--
Fax
--
Country
United States
ProdList
446
Advantage
71
Tecoland Corporation
Tel
--
Fax
--
Email
info@tecoland.com
Country
United States
ProdList
275
Advantage
50
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
LKT Laboratories, Inc.
Tel
--
Fax
--
Email
info@lktlabs.com
Country
United States
ProdList
2164
Advantage
64
More
Less

View Lastest Price from Sorafenib tosylate manufacturers

Hebei Zhuanglai Chemical Trading Co Ltd
Product
Sorafenib Tosylate 475207-59-1
Price
US $150.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
500kg
Release date
2024-12-03
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Sorafenib tosylate 475207-59-1
Price
US $0.00-0.00/Kg/Drum
Min. Order
1KG
Purity
99%min
Supply Ability
500KGS
Release date
2021-09-13
Shanghai UCHEM Inc.
Product
Sorafenib tosylate 475207-59-1
Price
US $44.00-593.00/g
Min. Order
5g
Purity
0.98
Supply Ability
25kg
Release date
2023-12-11

475207-59-1, Sorafenib tosylateRelated Search:


  • SORAFENIB TOSYLATE
  • Sorafenib & its intermediates
  • Sorafinib mesylate
  • 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
  • Sorafenib Tosylate(Bay 43-9006,Nexavar)
  • SORAFENIB TOSYLATE (BAY 43-9006 TOSYLATE)
  • BAY 43-9006;BAY43-9006
  • 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate)
  • Sorafenib (BAY-43-9006)
  • Sorafenib 475207-59-1
  • Sorafenib tosylate-002
  • Sorafenib tosylate(Nexavar,SORENIC)
  • N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate Sorafenib Tolsylate
  • N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate
  • 2-PyridinecarboxaMide, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-, 4-Methylbenzenesulfonate
  • Sorafenib Tosylate (Nexavar)
  • Sorafenib (Nexavar)
  • Sorafenib tosylate API
  • 1-(4-Chloro-3-(trifluoroMethyl)phenyl)-3-(4-((2- (MethylcarbaMoyl)pyridin-4-yl)oxy)phenyl)urea Mono(4- Methylbenzenesulfonate)
  • 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1)
  • Sorafenib TsOH salt
  • Sorafenib, p-Toluenesulfonate Salt, >99%
  • Sorafenib &amp
  • Sorafenib tosylate, >=99%
  • 4-[4-[[[[4-chloro-3-((trifluoromethyl))phenyl]amino]carbonyl]amino]phenoxy]-N-methylpyridin-2-carboxamide tosylate (1:1)
  • 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrim
  • Sorafeni tosylate
  • CL050
  • Sorafenib degradation (Sorafenib)
  • 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-2-pyridinecarboxamide Tosylate
  • 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N2-methylpyridine-2-carboxamide mono (4-methylbenzenesulfonate)c
  • Sorafenib tosylate USP/EP/BP
  • Sorafenib Tosylate (MFDS)
  • Bay 43-9006 (Tosylate)
  • Sorafenib Tosylate (Bay 43-9006
  • Sorafenib tosylateQ: What is Sorafenib tosylate Q: What is the CAS Number of Sorafenib tosylate Q: What is the storage condition of Sorafenib tosylate Q: What are the applications of Sorafenib tosylate
  • Sorafenib toluene sulfonate
  • 1,8-Butanediol,monomethanesulfonate
  • 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide 4-methylbenzenesulfonate
  • Toluenesulfonic acid sorafenib
  • Sorafenib (BAY 43-9006) tosylate
  • Pinacolborane Impurity 11
  • Sorafenib tosylate, 10 mM in DMSO
  • 475207-59-1
  • C21H16ClF3N4O3C7H8SO
  • C21H16ClF3N4O3C7H8O3S
  • C29H26F3N7O4S
  • C28H24ClF3N4O6S
  • Bay 43-9006
  • API
  • Inhibitors
  • MAPK